IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements and discoveries in the field of hematology compiled in an easy-to-digest format. It highlights research breakthroughs, clinical trial results, interesting case studies, and important health advisories – all within the last week. This is a valuable tool for medical professionals with limited time to stay up-to-date on the ever-evolving world of hematology.

IACH News of the week

News of the Week – July 7, 2024 (CLICK TO VIEW)

  • Venetoclax and hypomethylating (VEN-HMA) agents in octogenarians and nonagenarians with acute myeloid leukemia (AML).
  • Efficacy and safety of bendamustine‐containing bridging therapy (BT) in relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients receiving CD19 chimeric antigen receptor (CAR) T-cells.
  • Molecular diagnosis of primary CNS lymphoma (PCNSL) in 2024 using MYD88Leu²⁶⁵Pro and IL-10.
  • Response and resistance to menin inhibitor in upstream binding transcription factor (UBTF-TD) acute myeloid leukemia (AML).
  • Pembrolizumab and low-dose, single-fraction radiotherapy (RT) for patients with relapsed or refractory multiple myeloma (RRMM).

News of the Month- July 4, 2024 (CLICK TO VIEW)

  • Post-transplant cyclophosphamide (PTCy) at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin (ATG) in haploidentical transplantation (Haplo-HCT) with myeloablative conditioning (MAC).
  • Younger unrelated donors may be preferable over HLA match in the post-transplant cyclophosphamide (PTCy) era: a study from the ALWP of the EBMT.
  • Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation.
  • How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.
  • Yttrium-90 Anti-CD25-BEAM-Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Peripheral T Cell Lymphoma (PTCL).
  • Vedolizumab for the prevention of intestinal acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): a randomized phase 3 trial.
  • Evaluation of European LeukemiaNet (ELN) 2022 risk classification in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) for acute myeloid leukemia (AML): Identification of a very poor prognosis genetic group.
  • Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia (T-ALL): a registry-based study by the EBMT acute leukemia working party.
  • Anti-thymocyte globulin (ATG) or post-transplant cyclophosphamide to prevent graft-versus-host disease (GVHD) in matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (allo-HSCT)?
  • Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation (AlloSCT): The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
  • Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic stem cell transplantation (AlloSCT).
  • Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM).
  • Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma (PCNSL): results of Alliance 51101.
  • Graft Failure (GF) Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (AlloSCT) Using Post-Transplant Cyclophosphamide (PTCy).

News of the Week – June 30, 2024 (CLICK TO VIEW)

  • Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma (RRMM).
  • Brigatinib in Anaplastic lymphoma kinase (ALK)–positive anaplastic large-cell lymphoma (ALCL) after Failure of Brentuximab Vedotin
  • Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1).
  • Risk of second tumors and T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy.
  • Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia (ET).
  • Serum mass spectrometry for treatment monitoring in patients with relapsed/refractory multiple myeloma (RRMM) receiving chimeric antigen receptor (CAR) T-cells.

News of the Week – June 23, 2024 (CLICK TO VIEW)

  • Phase 3 study (IMROZ) results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) versus VRD for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)
  • Glofitamab (CD20:CD3 bispecific antibody) plus gemcitabine and oxaliplatin (Glofit-GemOx) versus Rituximab(R)-GemOx for Relapsed/Refractory (R/R) Difusse Large B-Cell Lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
  • First results of the APOLLO trial: a randomized phase III study to compare arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA [arm A]) versus standard ATRA plus Idarubicin (AIDA regimen [arm B]) for patients with newly diagnosed, high-risk acute promyelocytic leukemia (HR-APL)
  • ENERGIZE: a global phase 3 double-blind, randomized, placebo-controlled study of mitapivat demonstrating efficacy and safety in adults with alpha- or beta-non-transfusion-dependent thalassemia (α- or β-NTDT)
  • Asciminib (ASC) provides superior efficacy and excellent safety and tolerability versus tyrosine kinase inhibitors (TKI) in newly diagnosed chronic myeloid leukemia (ND-CML) in the pivotal ASC4FIRST study
  • The landscape of TP53 mutations and their prognostic impact in Chronic Lymphocytic Leukemia (CLL)
  • Acalabrutinib (acala) plus bendamustine and rituximab (BR) in untreated mantle cell lymphoma (MCL): results from the phase 3, double-blind, placebo-controlled ECHO trial
  • Guidelines session: EHA-ESMO Clinical Practice Guideline on primary central nervous system lymphoma (PCNSL)

News of the Month – June 7, 2024 (CLICK TO VIEW)

  • Abstract number: e1901. Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy
  • Abstract number: 7073. Survival outcomes after autologous stem cell transplantation in T follicular helper type lymphoma
  • Abstract number: e19043. Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR)
  • Abstract number: e1903. Relapsed Hodgkin lymphoma autologous stem cell transplant long term follow up
  • Abstract number: 7032. Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
  • Donor lymphocyte infusion (DLI) after allogeneic hematopoietic cell transplantation (allo-HCT) for hematological malignancies.
  • From 50th Annual Meeting of the EBMT
  • Fecal microbiota transplantation for high-risk treatment-naïve acute graft-versus-host disease (GVHD)
  • Peripheral blood (PB) stem cell versus bone marrow (BM) graft in reduced intensity conditioning (RIC) haploidentical hematopoietic stem cell transplantation (Haplo-SCT) for acute myeloid leukemia (AML) in complete remission (CR)
  • Improved outcome of allogeneic transplantation (AlloSCT) in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide (PTCy) and reduced duration of immune suppression
  • Efficacy of autologous (AutoSCT) and allogeneic hematopoietic cell transplantation (AlloSCT) in adults with acute promyelocytic leukemia (APL)

News of the Week – June 2, 2024 (CLICK TO VIEW)

  • Oral azacitidine in patients with relapsed or refractory follicular helper T-cell lymphoma
  • Risk stratification in Waldenström macroglobulinemia
  • VEXAS syndrome and thrombosis
  • Tattoos as a risk factor for malignant lymphoma
  • Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor (CAR)-T cell therapy in clinical practice for relapsed and refractory multiple myeloma

News of the Week – May 26, 2024 (CLICK TO VIEW)

  • Monoclonal Gammopathy of Undetermined Significance
  • Multiple myeloma and minimal residual disease
  • Multiple myeloma and chimeric antigen receptor-T cell therapy
  • Relapsed/refractory large B‐cell lymphoma

News of the Week – May 19, 2024 (CLICK TO VIEW)

  • Mature T- and NK-cell neoplasms
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Acute lymphoblastic leukemia
  • Multiple myeloma

News of the Week – May 12, 2024 (CLICK TO VIEW)

  • Measurable residual disease in multiple myeloma
  • “Minimal” residual disease in multiple myeloma
  • Untreated mantle cell lymphoma
  • Immune thrombotic thrombocytopenia purpura treatment
  • Relapsed or refractory primary mediastinal large B-cell lymphoma
  • Relapsed or refractory marginal zone lymphoma

News of the Week – May 5, 2024 (CLICK TO VIEW)

  • Chimeric antigen receptor (CAR) T-cells, bispecific antibodies (BsAbs), and relapsed and refractory large B-cell lymphoma (R/R LBCL)
  • Chimeric antigen receptor (CAR) T-cells and Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
  • Myelodysplastic syndromes (MDS)
  • Acute myeloid leukemia (AML)
  • Monoclonal B-cell lymphocytosis (MBL)

News of the Week – April 28, 2024 (CLICK TO VIEW)

  • Hemoglobinopathies & gene edition
  • Chimeric antigen receptor T cell (CAR T) therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  • Primary sinonasal diffuse large B-cell lymphoma (PSDLBCL)
  • Polycythemia vera (PV)
  • Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome
  • Post-transplant lymphoproliferative disorder (PTLPD)

News of the Week – April 21, 2024 (CLICK TO VIEW)

  • Chronic graft-vs-host disease (cGVHD)
  • Immune effector cell therapy-associated cytokine release syndrome
  • Multiple myeloma (MM) and chimeric antigen receptor T (CAR T) cell therapy
  • Non-Hodgkin lymphoma (NHL) and bispecific antibodies (BsAb)
  • Diffuse large B-cell lymphoma (DLBCL)

News of the Week – April 14, 2024 (CLICK TO VIEW)

  • Acute myeloid leukemia (AML)
  • Infections in secondary hypogammaglobulinemia in hematological malignancies.
  • Relapsed/refractory multiple myeloma (RRMM)
  • Cardiotoxicity and non-Hodgkin lymphoma (NHL)
  • Triple negative-primary myelofibrosis (TN-PMF)
  • Mature T-cell lymphomas (TCL) and chimeric antigen receptor T (CAR T) therapies

News of the Week – April 7, 2024 (CLICK TO VIEW)

  • AL amyloidosis
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Extranodal natural killer/T cell lymphoma (ENKTL)
  • Chimeric antigen receptor T (CAR T) therapies
  • Acute myeloid leukemia (AML)

News of the Week – March 31, 2024 (CLICK TO VIEW)

  • Primary immune thrombocytopenia (ITP) therapies
  • Primary testicular lymphoma (pTL)
  • Hemophilia B
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Multiple myeloma (MM)
  • Hematopoietic cell transplantation (HCT) and cellular therapies.

News of the Week – March 24, 2024 (CLICK TO VIEW)

  • Chimeric antigen receptor T cell (CAR-T) therapies
  • Acute myeloid leukemia (AML)
  • B-cell malignancies
  • Central nervous system (CNS) B-cell lymphoma
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
  • Myelofibrosis

News of the Week – March 17, 2024 (CLICK TO VIEW)

  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Acute myeloid leukemia (AML)
  • Chronic myeloid leukemia (CML)
  • Autoimmune hemolytic anemia (AIHA)

News of the Week – March 10, 2024 (CLICK TO VIEW)

  • Multiple myeloma (MM) – DREAMM-8 phase III trial (NCT04484623)
  • T-prolymphocytic leukemia (T-PLL) – phase II study (NCT03873493)
  • High-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) – safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine
  • Aplastic anemia (AA) – SOAR (NCT02998645)
  • Chimeric antigen receptor (CAR)-T-cell therapy – Rare secondary T-cell lymphomas after CD19- and BCMA-directed CAR-T-cell therapy